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Objectives: The aim of the study was to compare the access of patients with
rare diseases (RDs) to biotechnological drugs in several Central and Eastern
European countries (CEECs). We focused on the legislative pricing and reimbursement
requirements, availability of biotechnological orphan medicinal products (BOMPs) for
RDs, and reimbursement expenditures.
Methods: A questionnaire-based survey was conducted among experts from 10
CEECs: Bulgaria, Croatia, Estonia, Greece, Hungary, Poland, Romania, Slovakia, Serbia,
and Macedonia. The legal requirements for reimbursement and pricing of BOMPs were
collected. All BOMPs and medicines without prior orphan designations were extracted
from the European list of orphan medicinal products, 2017. The reimbursement status of
these medicinal products in 2017 in the public coverage of the included CEECs as well
as the share of their costs in relation to the total public pharmaceutical spending for the
period from 2014 to 2016 were defined.
Results: Our survey revealed that some differences in the legal requirements for pricing
and reimbursement of BOMPs amongst the countries included in the study. All European
Union countries have developed and implemented pharmacoeconomic guidelines with
or without some specific reimbursement requirements for orphan medicinal products.
Cost-effectiveness analysis, cost-utility analysis, Markov models, meta-analysis, and
discount levels of costs and results were required only in Bulgaria, Poland and Hungary.
The number of reimbursed BOMPs and biotechnological medicinal products for RDs
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without prior orphan designation was the highest in Hungary (17 and 40, respectively).
Patient-based reimbursement schemes were available only in Hungary for 11 out of 17
BOMPs. Poland and Greece have the highest pharmaceutical expenditure of reimbursed
BOMPs with are ∼214 million and 180 million EUR, respectively in the observed period
from 2014 to 2016. High proportion of the pharmaceutical expenditure on the reimbursed
biotechnological medicinal products for RDs for the observed period 2014–2016 is
presented in Bulgaria and Slovakia.
Conclusions: The non-European Union CEECs face a significant delay in the legal
implementation of pharmacoeconomic guideline for assessment of BOMPs. The access
to BOMPs is similar among the observed CEECs and the countries with the best access
are Hungary and Greece. The influence of BOMP expenditures on the budget in the
individual countries is significant.
Keywords: CEE countries, orphan medicinal products, reimbursement, rare diseases, biotechnology
INTRODUCTION
The definitions for rare diseases vary across the regions,
but the major classification criterion is associated with the
number of affected patients: not more than 5 in 10,000 in
the European Union and in Canada and fewer than 200,000
people in the USA (Stoimenova et al., 2011; Chicevaliev and
Aleksovska, 2016; Lacoste, 2018). Despite the limited number
of individuals affected by a particular rare disease the total
number of patients represents a significant percent (Schieppati
et al., 2008). More than 80% of all classified as rare diseases
(RDs) are of genetic origin, which defines the main purpose
of the scientists: to carry on more and more genetic research
in order to discover the intimate RDs pathogenic mechanisms
(Das et al., 2008; Altshuler et al., 2010; de Vrueh et al., 2013).
The lack of available effective and safe treatment for many rare
diseases is considered as an enormous problem (Elliott and
Zurynski, 2015)1,2, because every citizen should be provided with
quality medical care. On the other side the cost-effectiveness
of orphan medicines is difficult to be established. A lot of
efforts are being made so as innovative and targeted medicines
for the individual patients to be developed and authorized
in short terms, but this still does not solve the affordability
issues (Vella Bonanno et al., 2017). The number of medicines,
produced through biotechnological methods, such as enzymes,
cytokines, hormones, monoclonal antibodies, etc. has been
increasing tremendously in the recent years ensuring effective
and safe treatment targeting specific mediators (Bruggemeier,
Abbreviations: ATC, Anatomical Therapeutic Chemical Classification; BOMPs,
Biotechnological Orphan Medicinal Products; CEECs, Central and Eastern
European Countries; EU, European Union; GDP, Gross Domestic Product; HTA,
Health Technology Assessment; HAS, Haute Autorité de Santé; INN, International
Nonproprietary Name; IQWIG, The Institute for Quality and Efficiency in
Healthcare; NICE, National Institute for Health and Care Excellence; RDs, Rare
Diseases.
1WHO report, Priority diseases and reasons for inclusion. 6.19
2Rare diseases. Available online at: http://www.who.int/medicines/areas/
priority_medicines/Ch6_19Rare.pdf; http://static.correofarmaceutico.com/
docs/2016/12/12/qiihi_outlook_for_global_medicines_through_2021.pdf
2006; Bellomo et al., 2017; Geynisman et al., 2017). In the
recent years, gene transfer technology has been developed and
implemented for the therapy of rare genetic disorders (Han et al.,
2017; Mavilio, 2017). Developing cell, gene, nanobiotechnology-
based and other biotechnology therapies ensure meeting the
unmet medical need in a number of rare diseases (Brooks et al.,
2016; Nance et al., 2018).
Despite the significant clinical benefits that the biologic
treatments offer their costs are much higher than in case of
the small molecules. Therefore, they have a significant financial
impact on the total health care budget as it is expected
to reach $75–90 billion in spending by 20213. This could
put additional pressure on the healthcare budgets which are
limited especially in the low and middle-income countries
and therefore could limit the patients’ access to therapy
(Moorkens et al., 2017). Kawalec et al. revealed that the
total expenditures on the reimbursement of biologic drugs
in the Central and Eastern European Countries (CEECs)
were seriously increasing for the period 2014–2015 as well
as more than 80% of the value in 2014 and more than
70% in 2015 was covered by the reimbursement of original
drugs in the same countries (Kawalec et al., 2017). The
mechanisms for cost reduction such as authorization of
biosimilars are implemented in order to be provided an
adequate patients’ access to treatment (Petigara and Anderson,
2008). For example, the growth rate in the expenditures for
biotechnological drugs could be decreased by ∼5% through
implementation of treatment with biosimilars. Restrictive
requirements about spending control mechanisms are available
in Europe such as the need for strict drug cost-value assessment,
defining of budget caps and pharma payback schemes, price
negotiations etc.
Health technology assessment and specific
pharmacoeconomic criteria are applied in every country so
as the cost-effectiveness of biologics for rare diseases have to
3Outlook for Global Medicines through 2021. Balancing Cost and Value.
QuintilesIMS Institute. 2016.
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be assessed for the purposes of their inclusion in the drug
list covered by public funds. Moreover, a higher threshold
than the conventional one is recommended for this group of
products in some countries (Longson, 2017; Kamusheva et al.,
2018).
Besides, the launching of biologics is accompanied by a
number of challenges and one of them is associated with the
provision of an equitable access facing differences in pricing
and reimbursement policies in every country (Ling et al., 2014;
Lybecker, 2016). Therefore, our main aim was to compare an
access to biotechnological drugs for patients with rare diseases
(RDs) in several CEECs. We have focused on the legislative
pricing and reimbursement requirements, the availability of
biotechnological orphan medicinal products (BOMPs) for RDs
and on their reimbursement expenditures. We explored several
research questions as the availability of biotechnological orphan
medicines in the reimbursement system in the considered
countries, their coverage from public resources, and market
access in reference to Health Technology Assessment (HTA)
requirements.
MATERIALS AND METHODS
In the current comparative analysis, we included
biotechnological OMPs, which were extracted from the
latest version of the List of orphan drugs published by Orphanet
in July 20174. Both lists of OMPs with and without prior orphan
designation were taken into consideration and the analysis was
presented separately. The comparative questionnaire-based
analysis was made for 24 biotechnological orphan medicines
and for 49 biotechnological medicines without prior orphan
designation.
A questionnaire-based survey was conducted among leading
experts from twelve CEEC: Bulgaria, Croatia, Estonia, Greece,
Hungary, Poland, Romania, Slovakia, Serbia, Macedonia, the
Czech Republic, and Latvia Only ten out of these 12 countries
gave their consent to take part in the survey and sent the
questionnaire with respective answers. Serbia and Macedonia as
non-EUmember states were selected so as a comparison between
non-EU and EU countries to be performed. The communication
was realized by e-mail using English language and the subsequent
answers had been received for a period of several months: from
October 2017 to February 2018.
The questionnaire written in English was standardized
according to the aim of the project and examined several aspects:
1. What are the existing legal requirements for pricing
and reimbursement of biotechnological orphan medicinal
products in the selected CEEC?
a) Is there a specific part in the pharmacoeconomic guideline
about biotechnological orphan medicinal products
(BOMPs)?
b) What are the basic principles of the included in the survey
CEEC’s pricing system?
4Orphanet List of Orphan drugs, July 2017.Avaialble online at: www.orphanet.net
c) Are there any discounts for the purposes of BOMPs
expenditures control?
d) Which are the specific requirements for reimbursement of
BOMPs?
2. What are the requirements for the preparation of
pharmacoeconomic/HTA dossiers of BOMPs?
a) Is there a separated threshold for cost-effectiveness
assessment of BOMPs?
b) Which are the main pharmacoeconomic methods, which
are obligatory for BOMPs?
c) Which are the additional non-economic considerations
taken into account for BOMPs?
3. Which are the BOMPs included in every local positive drug
list?
4. Which are the biotechnological medicinal products without
prior orphan designation intended to treat rare diseases which
are included in every local positive drug list?
5. What are the pharmaceutical expenditures paid by public
funds in the selected CEEC and what the share of BOMPs
from the total expenditures is for a 3-year period of time
2014–2016?
Lastly, the statistical analysis using MedCalc software was
performed on the basis of total amount of data on the reimbursed
BOMP collected in the survey. The share of BOMPs expenditures
in relation to total pharmaceutical expenditures for the observed
period of time was calculated for each individual country as well
as the number of BOMPs, reimbursed in all considered CEEC.
The collected information from each country was extracted,
classified and analyzed by the experts.
RESULTS
Pricing and Reimbursement Requirements
for BOMPs in Selected CEE Countries
The essential legal requirements for reimbursement of
biotechnological orphan medicinal products in the selected
CEECs were summarized and presented in Table 1. All EU
member states included in the analysis, except Greece and
Romania, have implemented pharmacoeconomic and Health
Technology Assessment guidelines in accordance with the
recommendations. The Hungarian Guidelines were first
published in 2003 (Szende et al., 2002) and the last revision was
issued in February 2017 (Gyógyszereink, 2017). Balkan countries
outside the EU, Serbia, and Macedonia, have not followed any
official guidelines yet.
A special section of the guidelines, indicated exclusively for
orphan medicines is available in just a few countries: Bulgaria,
Slovakia and Croatia. Moral and ethical considerations (equality,
fair and timely adequate access to safe and effective treatment),
some limitations about clinical indication (e.g., state of the
disease, predefined biochemical parameters, lack of alternative
treatment), as well as the number of patients or the age of the
patients, providing Markov model for presenting the outcomes
etc. are mentioned in the additional section about OMPs of the
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Bulgarian guidelines (Ministry of Health, Bulgaria, Regulation
No. 9 of 01.12. 2015 on the conditions and procedures for
conducting health technology assessment). The conventional
thresholds set in Slovakia (lower threshold (λ1): 35 times average
monthly salary and the upper threshold (λ2): 41 times average
monthly salary) are not applicable for orphan drugs indicated in
the therapy of rare diseases, where number of patients eligible
for treatment with a medicinal product based on the indication
approved in marketing authorization is lower than 1: 50,000 in
the Slovak republic. In such cases, there is no need for pharmaco-
economic analysis.
Reimbursement decisions are based on the conventional
requirements which are valid for all medicines. The conventional
pharmacoeconomic analysis and HTA dossiers include evidence
for cost-effectiveness and present the budget impact of the new
medicines taking into account the current treatment strategies.
The reimbursement of BOMPs in some countries such as
Bulgaria, Serbia, Hungary, Estonia andGreece is based on specific
additional criteria such as clinical indications, the age of patients,
limitation in the number of treated patients and severity of
the disease. These adopted limitations ensure an adequate cost
containment measure for the local pharmaceutical budgets.
The deadlines for pricing and reimbursement (P&R) decisions
for the EU members are according to the Transparency Directive
−180 days. In Serbia it is 120 days for reimbursement and 90
days for pricing whereas no timeline is specified in Macedonia.
In Hungary the duration of the P&R procedure itself is 90
days. Moreover, 43 days are needed for the HTA Office within
the whole P&R procedure to evaluate the dossier and make a
suggestion for reimbursement. In Bulgaria for all new INNs the
procedure is extended to 180 days and included an opinion given
by the HTA Committee and final decision made by the National
Council on Pricing and Reimbursement.
External reference pricing is valid for all medicinal products
as well as for BOMPs in all considered countries. However,
the number of chosen reference countries and the external
pricing rules differ among the countries. In Bulgaria the
manufacturing price must be not higher than the lowest price
among the 17 reference countries. Whereas MPs price in Greece
is defined as the average of the three lowest in 27 European
Union countries. Croatia uses only 5 EU countries as reference
countries. The final price in Slovakia may not exceed the average
of the three lowest prices of the same medicine available on
pharmaceutical markets across the European Union (EU). In
Hungary, Norway and Switzerland there are also considered
as reference countries as the lowest price within the basket
of countries is defined as the reference list price. Poland uses
31 countries of the European Union and European Economic
Area as reference countries and the price in Poland should
be lower than the lowest price of the drug in the reference
countries. Estonia compares the manufacturer price only with
3 countries as it should be lower than the same price in
Latvia, Lithuania, and Slovakia. The criterion used in Macedonia
is the lowest price as the price is negotiated and provided
through public procurement by the Ministry of Health. The
other non-EU country included in the survey, Serbia, has two
baskets: the first basket consists of 3 EU countries, while the
second one includes European country where the product is
manufactured or EU countries that have the same MP on the
market.
Obligatory confidential discounts on different levels are
applied in most countries. Besides, varieties of Risk Sharing
Schemes are adopted in Greece and Poland valid for majority
medicinal products.
Structure of the Pharmacoeconomic
Analysis/HTA Dossier in the Considered
CEEC
The main pharmacoeconomic methods used in almost all CEEC
countries (except for Romania) are cost-effectiveness, cost-
utility analysis and in some cases—cost-minimization. A proxy
scorecard is applied in Romania, so CEA and CUA are not
applicable and the reimbursement decision is mainly based on
that taken in other countries such as Germany, UK, France, and
Scotland.
Differences in the thresholds for both orphan medicines
and non-orphan medicines are not defined in almost all CEEC
except Slovakia. Estonia, Greece, Romania, and Serbia do not
use any threshold for cost-effectiveness assessment of all MPs. In
Bulgaria, Poland, Hungary, and Croatia the threshold is the same
as for all non-orphan medicines: 1–3 × gross domestic product
per capita (GDP/ capita).
Budget impact analysis and clinical and cost comparisons with
appropriate reference drugs are valid for all considered countries.
Application of Markov models is obligatory in some countries
(Bulgaria, Croatia, Hungary, Poland) while optional in others
(Slovakia, Estonia). Obligatory modeling is not yet implemented
in the guidelines in Greece, Serbia and Romania. Provision of
meta-analysis (where eligible) is also a requirement, defined
in the Bulgarian, Croatian, Hungarian, Polish and Estonian
pharmacoeconomic and HTA guidelines. The discounted level is
strictly defined to be 5% for both costs and clinical results in most
of the countries. The only exception is Poland, where the level for
clinical results is lower than the level for the costs−3.5 vs. 5%.
The final reimbursement decision is a result of a detailed
and transparent appraisal, which in some CEEC is based on
reports published in other countries—UK, Germany, France,
and Scotland. If NICE, HAS or IQWIG gave a negative
recommendation the procedure in Bulgaria is terminated with a
negative reimbursement decision. On the other side, these reports
are just additional aspects considered in Poland as they did not
directly influence the final reimbursement recommendations or
reimbursement decisions.
The social and economic burden of the disease, its rarity
and seriousness are considered in all countries. They should be
represented in the dossier and the final decision is based on a set
of economic, social and ethical considerations.
Reimbursed BOMPs and Biotechnological
MPs Without Orphan Designation in CEEC
According to the List of Orphan Drugs in Europe, published
in July, 2017 the number of biotechnological drugs is 24 and
the number of biotechnological MPs without prior orphan
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TABLE 3 | Biotechnological orphan medicinal products intended to treat rare diseases included in the local positive drug lists.
INN ATC code Bulgaria Croatia Estonia Greece Hungary Macedonia Poland Romania Serbia Slovakia
Cerliponase alfa A16AB17 – – – – – – – – – –
sebelipase alfa A16AB14 – – – – – – – – – –
teduglutide A16AX08 – – – – – – – – – –
asfotase alfa A16AB13 – – – – PBR*** – – – – –
elosulfase alfa A16AB12 – – – – PBR*** – – – Registered,
not
reimbursed
-
velaglucerase alfa A16AB10 – + - +/HC** PBR*** – + – – +
Eftrenonacog alfa B02BD04 – – – +/HC** + – – – – –
Human coagulation
factor X
B02BD13 – – – - + + – – – Only in the
combination:
ATC Group
B02BD01
Defibrotide B01AX01 – – – +/HC** – – – – – –
albutrepenonacog
alfa
B02BD04 – – – +/HC** + - - - - -
romiplostim B02BX04 + + +/AC* + - - + +/HC** +
Alipogene
tiparvovec
C10AX10 – – – – – – – – – –
afamelanotide D02BB02 – – – – PBR*** – – – – –
mecasermin H01AC03 – – – +/AC* – – + – – –
parathyroid
hormone
H05AA03 – – – - – – – – – –
Brentuximab
vedotin
L01XC12 + + – +/HC** + – + – +/HC** –
Ofatumumab L01XC10 + + +/AC* +/HC** PBR*** - – + Registered,
not
reimbursed
+
Blinatumomab L01XC19 – – – +/HC** PBR*** - – – – –
daratumumab L01XC24 – – – +/HC** PBR*** - – – – –
Dinutuximab beta L01XC16 – – – - PBR*** - – – – –
Obinutuzumab L01XC15 – + – +/HC** + - + - Registered,
not
reimbursed
+
olaratumab L01XC27 – - – – PBR*** - – – – –
eculizumab L04AA25 – + – +/HC** PBR*** - – – – –
siltuximab L04AC11 – - – +/HC** PBR*** - – – – –
Number of BOMPs 3 6 1 13 17 1 4 2 5 4
ATC, Anatomical Therapeutic Chemical Classification System. *AC, ambulatory care. **HC, hospital care. ***PBR: Not in the positive list, but available and reimbursed through
‘Patientbased reimbursement system.
designation is 49. As a result of comparison between this list
and the reimbursement lists available in all included in the
current analysis CEEC, Hungary and Greece are the countries
with the highest number of biotechnological orphan (71 and
54%, respectively) and non-orphan (82 and 88%, respectively)
medicinal products for rare diseases (Tables 3, 4, Figure 1). The
countries with themost limited access to biotechnological orphan
medicines are Macedonia and Estonia with only one medicine
reimbursed, followed by Romania, Serbia (n = 2), Bulgaria (n
= 3), Slovakia (n = 4), and Croatia (n = 7). Using the first
level of Anatomical Therapeutic Chemical classification system
(ATC), the prevailing biotechnological OMPs are from group ‘L
– Antineoplastic and immunomodulating agents’ (9 medicinal
products). In Hungary some medicines are not included in the
positive list but they are available and reimbursed through the
so-called ‘Patient-based reimbursement system’ (n= 11).
The share of antineoplastic and immunomodulating drugs
among all biotechnological medicines for RDs without prior
orphan designation is the highest—it is around 39%. Most
reimbursed medicines in almost all observed CEEC are from the
group of antineoplastic agents: 29% in Bulgaria, 37% in Croatia,
37% in Greece, 44% in Poland. Greek healthcare fund reimbursed
43 biotechnological MPs without prior orphan designation, most
of which are in the group of antineoplastic (37%), followed by
blood products−28%. Surprisingly, the number of reimbursed
medicines in Romania is lower than in Serbia, which is non-
European union (non-EU) member state−11 vs. 22MPs. Poland,
Bulgaria, Croatia, and Slovakia have included almost equal
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TABLE 4 | Biotechnological medicinal products without prior orphan designation intended to treat rare diseases included in the local positive drug lists.
ATC code Bulgaria Croatia Estonia Greece Hungary Macedonia Poland Romania Serbia Slovakia
laronidase A16AB05 Only price;
it’s not
reimbursed
+ – +/HC** PBR*** – + + Registered,
not
reimbursed
+
imiglucerase A16AB02 + + – +/HC** PBR*** – + – Registered,
not
reimbursed
+
idursulfase A16AB09 + + – +/HC** PBR*** – + + Registered,
not
reimbursed
-
agalsidase beta A16AB04 + + +/HC +/HC** + – – + Registered,
not
reimbursed
+
Alglucosidase alfa A16AB07 + + +/HC** PBR*** – + + Registered,
not
reimbursed
+
Galsulfase A16AB08 Only price;
it’s not
reimbursed
+ - +/HC** PBR*** – + – – –
agalsidase alfa A16AB03 + + +/HC** +/HC** PBR*** – + - +
octocog alpha B02BD02 - + - +/HC** + - + – + +
nonacog alpha B02BD04 + +/HC** + + +
Human protein c B01AD12 – – – +/HC** - – – – – Only in the
combination:ATC
Group
B02BD01
C1 inhibitor
(human)
B02AB03 + – – +/HC** + + + – – +
efmoroctocog
alfa
B02BD02 + – – +/HC** + – + – – +
human
coagulation factor
IX
B02BD13 + + + +/HC** + + + + +
turoctocog alpha B02BD02 + + - +/HC** + – + – Registered,
not
reimbursed
+
eptacog alpha B02BD08 + + – +/HC** + + - - + +
catridecacog B02BD11 – – – +/HC** + – – – – –
Susoctocog alfa B02BD14 – – – – – – – - – –
Moroctocog
alpha
B02BD02 + + +/HC** + + +
human alpha1-
proteinase
inhibitor
B02AB02 - + – +/HC** – – – – – –
Nonacog gamma B02BD04 - - – – – – + – – –
conestat alfa B06AC04 + + + - + – – +
human
coagulation factor
viii/ von
willebrand factor
B02BD06 + + + +/HC** + + + +
Evolocumab C10AX13 + – – +/AC* – – – – Registered,
not
reimbursed
+
follitropin alfa G03GA05 + + +/AC* +/AC* + + + - + +
follitropin beta G03GA06 + + +/AC* +/HC** + + + - + +
(Continued)
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TABLE 4 | Continued
ATC code Bulgaria Croatia Estonia Greece Hungary Macedonia Poland Romania Serbia Slovakia
somatropin H01AC01 + + +/AC* +/HC** + + + - + +
Pegvisomant H01AX01 + + – +/HC** PBR*** – – + – +
thyrotropin alfa H01AB01 + + – +/HC** + – + + Registered,
not
reimbursed
+
human normal
immunoglobulin
J06BA + + +/HC** +/HC** + + + + + +
human hepatitis b
immunoglobulin
J06BB04 + + +/HC** +/AC* + + - - + -
adalimumab L04AB04 + + +/HC** +/AC* + - + – + +
bevacizumab L01XC07 + + +/HC** +/AC* + - + – + +
elotuzumab L01XC23 - - - - - - - – – –
etanercept L04AB01 + + +/HC** +/HC** + - + – + +
cetuximab L01XC06 + + +/HC** +/HC** + - + – + +
Filgrastim L03AA02 + + +/HC** +/AC* + + – + +
Trastuzumab L01XC03 + + +/HC** +/HC** + + + – + +
Canakinumab L04AC08 - - - +/AC* + - - – - -
interferon
alpha-2b
L03A B05 - + - +/AC* + + + + + +
Pembrolizumab L01XC18 - - - +/HC** + - + - + -
anakinra L04AC03 - + - +/HC** - - + - - -
Rituximab L01XC02 + + +/HC** +/HC** + + + + + +
pegaspargase L01XX24 – + - - - - + - - -
nivolumab L01XC17 – - +/HC** +/HC** + - + - Registered,
not
reimbursed
-
abatacept L04AA24 – – – +/HC** + – – - – +
Tocilizumab L04AC07 + + – +/HC** + – + – + +
golimumab L04AB06 + + – +/AC* + + – + +
Asparaginase L01XX02 – + – +/HC** + + – – +
ibritumomab
tiuxetan
V10XX02 – – – – + – – – – +
Number of BOMPs 33 35 17 43 40 12 34 11 31 35
ATC, Anatomical Therapeutic Chemical Classification System. *AC, ambulatory care. **HC,hospital care. ***PBR: Not in the positive list, but available and reimbursed through
‘Patient-based reimbursement system.
number of biotechnological non-orphan drugs−34, 31, 35, and
35.
Some of the biotechnological drugs are not reimbursed but are
authorized and available on the market with a price. Therefore,
patients have restricted affordability to these medicinal products
due to their high price and lack of reimbursement status.
Reimbursement Expenditures for BOMPs
in CEE Countries
Total pharmaceutical expenditures covered by the local public
fund have increased for 3-year period of time (2014–2016)
in all countries, included in the survey (Table 5, Figures 2,
3). The same tendency is revealed for the pharmaceutical
expenditures for biotechnological drugs for rare diseases and
for their share of the total costs. Romania and Hungary were
excluded due to lack of reliable data. Greece is characterized
by relatively stable expenditures and it is the only country
in which the total reimbursement expenditures decreased in
2015 in comparison with 2014. The lowest are both total
reimbursed costs and the reimbursed costs for biotechnological
drugs for RDs in Macedonia, Serbia, and Estonia, followed
by Bulgaria, Croatia, and Slovakia. The highest are the
costs in Poland and Greece in the observed period as
their average values are ∼214 million and 180 million euro,
respectively. However, the expenditures per million populations
are the highest in Slovakia (average value for the observed
period−35million euro), followed by Croatia, Greece, and
Bulgaria (Figure 3).
The shares of expenditures on the reimbursement of
biotechnological drugs for RDs in the individual countries vary
between 0.5% in Serbia and 16.8% in Slovakia in 2014. Similar
variation is observed in 2015 and 2016: between 0.52% in Serbia
and Estonia and 16.6% in Slovakia and between 0.7% in Serbia
and 19% in Bulgaria, respectively for both years. The most
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FIGURE 1 | Number of biotechnological orphan medicines and biotechnological MPs for rare disease without prior orphan designation in the selected CEEC. MPs,
medicinal products; OMPs, orphan medicinal products.
significant is the increasing share of biotechnological drugs in
Bulgaria: from 8% in 2014 to 19% in 2016 (Figure 4).
DISCUSSION
To the best of our knowledge this is the first study comparing
the legislative requirements, patients’ access to biotechnological
medicines for rare diseases and financial impact of these
medicinal products on the pharmaceutical budget of low- and
middle-income countries from Central and Eastern Europe
(CEECs). Our work is the first to make such a comparison
and produce significant results that can be used as a basis for
conducting further detailed studies among more countries in
the region, taking into account the level of reimbursement,
co-payment, and dynamics of the number of BOMPs in local
markets. Our study provides new evidence about the access to
orphanmedicines in countries with similar macroeconomics that
was gathered over a period of 3 years and confirms previously
published statements that orphan legislation principles as well
as the availability and accessibility of ODs vary among the
EU countries (Iskrov et al., 2012; Logviss et al., 2016). The
study is based on expert opinion and evidence from the
literature (Vogler et al., 2015; Kawalec et al., 2017) (Baltic
guideline)5.
Despite the implementation of relevant legislation and
pharmacoeconomic criteria for cost-effectiveness assessment of
BOMPs, their number varied significantly among CEECs. This
could influence the access to appropriate treatment and could
worsen patients’ condition and reduce significantly the quality
5Baltic guideline for pharmacoeconomic assessment, https://www.sm.ee/
sites/default/files/content-editors/eesmargid_ja_tegevused/Tervis/Ravimid/
balti_juhis_ravimite_farmakooekonoomiliseks_hindamiseks.pdf
of life of patients with rare diseases for whom innovative
biotechnological medicines are not reimbursed. Limited access
to adequate therapy could lead to additional healthcare costs
as well as to reduced productivity and losses for the society
as a whole. Most of the biotechnological medicines for RDs
reimbursed in CEECs belong to the group of antineoplastic
and immunomodulating agents according to ATC classification
system, which demonstrates the increasing impact of oncological
diseases on public healthcare spending. Our analysis shows that
the access to BOMPs in all CEECs has been improving in the
recent years and the countries with the best access are Greece and
Hungary. What is more, we can acknowledge that the number of
reimbursed orphan drugs in a given country is correlated with
the time of joining the EU. Orphan drugs are reimbursed to
a lesser extent in the new EU member states, which could be
explained by their limited healthcare spending as compared with
the countries that joined EU earlier (de Varax et al., 2004; Pavlović
et al., 2013). Our results are in accordance with the results of
another study in which it is shown that Greece ensures more
adequate access to orphan drugs than Romania and Bulgaria
(Kamusheva et al., 2013). Stoimenova et al. analyzed the access
to orphan medicines in Bulgaria and the share of biotechnology-
derived products reimbursed for rare diseases in Bulgaria in 2011
(Stoimenova et al., 2011) Comparing our results with the results
of this study, it is obvious that the access to biotechnology-
derived medicines which are intended to treat rare diseases has
been improving in Bulgaria in the recent years from around
13 in 2011 to 36 in 2017. The number of reimbursed BOMPs
in Serbia is limited probably due to incomplete compliance
with European Union legislation (Pavlović et al., 2013) and
high prices of BOMPs, which is considered a limiting factor
for their inclusion in the positive drug list (Pejčić and Iskrov,
2016).
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FIGURE 2 | Total pharmaceutical expenditures paid by the public fund in each country in 2014–2016.
FIGURE 3 | Total expenditures per million population paid by the public fund for biotechnological drugs for rare disease in each country in 2014–2016.
Additional approaches for ensuring access to BOMPs
through other mechanisms are reported only in Hungary. An
example of such mechanism is the patient-based reimbursement
system. Hungarian patients have the possibility to receive
reimbursement for high-priced medicines not included in
the reimbursement list through a special budget allocated
on an individual basis (Németh et al., 2017). Patients with
rare diseases in all other countries included in the study are
provided appropriate treatment through hospital budgets
and local health insurance funds. Macedonia, as a non-
EU member state, faces a lot of challenges in ensuring
access and affordability to BOMPs, which is probably
associated with the lack of adequate financing (Zlatareva
et al., 2013).
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FIGURE 4 | Share of the costs for biotechnological drugs for rare diseases of the total reimbursed pharmaceutical costs in all CEEC for the period 2014–2016.
The financial burden of BOMPs is significant in CEECs
considering limited funding for pharmaceuticals in these
countries, especially non-European member states, Macedonia
and Serbia. The main cost driver is the price of the
biotechnological medicines resulting from the innovative
methods used for their manufacturing. Reimbursement of these
high-priced groups of medicines is also determined by their
ability to fulfill the unmet medical needs, especially of patients
with rare diseases. The inclusion of the so-called biosimilars,
which are as safe and effective as the reference medicine (Dowlat
et al., 2016), might significantly reduce the financial burden of
biotechnological medicines. As Dowlat state orphan medicines
form a significant part of the healthcare spending because of their
high cost, which is also the main reason for a drug not always to
be reimbursed (Dowlat, 2016). Therefore, the opportunity for the
development of biosimilars for BOMPs should be highlighted.
Moreover, Dowlat et al. emphasizes that biosimilar development
would be gradual due to legislative hurdles, market and data
protection and exclusivity of the originators and the protection
of intellectual property.
All these inequalities between the CEECs regarding BOMPs
and biotechnological MPs for RDs could be explained with the
differences in the reimbursement approaches, but mostly due
to the financial restrictions determined by the governments.
Shared projects and collaboration among the CEECs could
improve the national reimbursement systems and enhance the
knowledge of national experts for the purposes of preparing
more precise and valuable pharmacoeconomic analyses for
biotechnological orphan medicines. The adaption of well-
working risk-sharing schemes, patients oriented legislative
changes in the healthcare sector, exploring and implementation
of the best reimbursement practices available worldwide could
significantly improve the patients’ access to biotechnological
treatment in poorer performing CEECs.
CONCLUSION
Our comparative analysis showed that despite the limited
number of patients with rare diseases, biotechnological
medicines for such diseases have a significant impact on
pharmaceutical spending of each CEEC. The tendency is for
slow increase in the share of BOMPs and BMPs for RDs of
the total costs (in some countries, e.g., Bulgaria, the increase
was two-fold). Therefore, the access to these medicines
and their affordability to the patients have been improving
in the recent years, which is especially visible in Hungary
and Greece. However, the non-European Union CEECs
such as Macedonia face a delay in the legal implementation
of a pharmacoeconomic guidelines for the assessment of
BOMPs. Despite the fact that Serbia is not in the EU, its
legislation in the area of reimbursement of BOMPs and
the level of patients’ access to treatment is similar to that
of Bulgaria, Slovakia and Estonia. The CEECs have similar
reimbursement requirements and there is a tendency for
developing the systems in line with the latest scientific,
pharmacoeconomic, and health technology assessment
guidelines.
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